A B S T R A C T Chronic administration of high doses
INTRODUCTION
It is well recognized that chronic administration of anticonvulsant drugs can produce a variety of disorders of vitamin D, mineral, and bone metabolism. Hypocalcemia, reduced serum 25-hydroxyvitamin D concentrations, elevated serum immunoreactive parathyroid hormone (PTH)l levels, reduced bone mass, and histologic evidence of osteomalacia have been reported in 10-60% of various anticonvulsant drug-treated populations (1) (2) (3) (4) (5) (6) . From the observation that administration of phenobarbital and diphenylhydantoin (phenytoin) (DPH) to humans and animals leads to induction of liver microsomal oxidase enzymes, with a consequent increased rate of catabolism of vitamin D and 25-hydroxyvitamin D to polar, presumably inactive products (7, 8) , it has been generally accepted that a reduction in the circulating levels of biologically active vitamin D metabolites plays a significant role in producing the derangements of mineral metabolism seen in this disorder.
On the other hand, several clinical studies have demonstrated that chronic DPH administration can also produce effects suggestive of end-organ resistance to the effects of PTH. Radiographic surveys of denti1Abbreviations used in this paper: cAMP, cyclic AMP; 1,25-(OH)2D, 1,25-dihydroxyvitamin D3; DPH, diphenylhydantoin (phenytoin); HCT, human calcitonin; PTH, synthetic parathyroid hormone . tion in patients receiving chronic DPH therapy have demonstrated a markedly increased incidence of root abnormalities, characteristic of those seen in hypoparathyroidism and pseudohypoparathyroidism (9, 10) . Moreover, calvarial thickening, another feature of chronic hypoparathyroid states, has been observed with increased frequency after prolonged DPH administration (11) . In addition, there is experimental evidence which suggests that anticonvulsant drugs may indeed have direct effects on mineral metabolism. Koch et al. (12) have reported that DPH appears to directly inhibit intestinal calcium transport in the rat and Harris et al. (9) have demonstrated that DPH can inhibit parathyroid extract-induced 45Ca release from mouse calvaria in vitro.
The purpose of the present studies was to examine the direct effects of DPH and phenobarbital on basal and hormone-mediated resorption and cyclic nucleotide generation in fetal rat long bone rudiments maintained in culture. Our results indicate that both drugs directly affect indices ofbone resorption and that DPH, in particular, interacts significantly with hormonally mediated resorption processes.
METHODS
Isolation and incubation. Bone resorption was measured in 5-day cultures of the midshafts of the radius and ulna of 19-day-old fetal rats with a modification of the technique of Raisz and Niemann (13 24 and 18 h before sacrifice. The animals were sacrificed by cervical dislocation and the fetuses were removed. Calcified midshafts of the radius and ulna of both forelimbs were dissected free of the cartilaginous epiphyses and adherent tissue, and then washed at 4°C in BGJb medium (Grand Island Biological Co., Grant Island, N. Y.) (14) . "Killed" rudiments were prepared by freeze-thawing three times after preculture. Individual rudiments were placed on small rafts of sterilized Millipore filters (Millipore Corp., Bedford, Mass.). These were in turn positioned on stainless steel grids on the surface of a 0.5-ml BGJb medium supplemented with 4 mg/ml bovine serum albumin fraction V (Armour Pharmaceutical Co., Phoenix, Ariz.) in multiwell culture plates (Microbiological Associates, Bethesda, Md.) and preincubated for 24 h at 37°C in an atmosphere of 95% 02, 5% CO2, at 95-98% relative humidity. Preincubation media were discarded after 24 h and the rudiments placed in fresh media containing appropriate concentrations of the test substances. The media were changed again at 48 h and the incubation continued for a total of 5 days after preculture.
In the 45Ca release studies, the incubation was terminated by placing the rudiments in 0.2 ml of 5% trichloroacetic acid at room temperature for 3 h. Then 1.0 ml ofTS-1 tissue solubilizer (New England Nuclear) was added for an additional 30 min, after which 7 ml of toluene-based scintillation cocktail was added for liquid scintillation counting. 100-,ul aliquots of 2-and 5-day culture media were dissolved in 0.6 ml TS-1 for 30 min. before the addition of 7 ml of scintillation cocktail. In the [3H]proline experiments media aliquots and bones were initially hydrolyzed in 6 N HCI (final concentration) at 110°C for 24 h.
[3H]Hydroxyproline in bone and media hydrolysates was then determined by the method of Prockop and Udenfriend (15) . Percent resorption in both the 45Ca and [3H]proline experiments was calculated as: (bone counts per minute/bone counts per minute plus total media counts per minute) x 100. Each data point was comprised of eight or more individual bone rudiment incubations, with the rudiments systematically divided so that equal numbers of radii and ulnae were included in each point. The statistical significance of differences between group means was calculated with a Student's t test.
Cyclic nucleotide generation. In experiments where bone cyclic AMP (cAMP) content was measured, after a 24-h preculture in control BGJb medium the rudiments were incubated for 24 h as described above in the presence or absence of the appropriate drug(s). They were then removed from the incubation wells and placed in 12 x 75-mm glass tubes (four rudiments per tube) containing 0.3 ml of fresh medium and preincubated for 15 min in room air at 37°C in a shaker bath at 90 oscillations/min. The media were then removed with a transfer pipet and replaced with 0.3 ml of fresh media supplemented with theophylline (10 mM) and containing the test hormone with or without drug. To terminate the reaction, the media were again aspirated off, 0.5 ml of 6% trichloroacetic acid was added, and the tubes placed in boiling water for 5 10 ,ug/ml directly into BJGb medium; 1,25-dihydroxyvitamin D (generously supplied by Hoffmann-La Roche, Inc., Nutley, N. J.) was dissolved to a concentration of 200 ng/ml in absolute ethanol; phenobarbital sodium (Elkins-Sinn, Inc., Cherry Hill, N. J.) was dissolved to a concentration of 100 mg/ml in sterile water; sodium diphenylhydantoin (Sigma Chemical Co., St. Louis, Mo.) was initially dissolved to a concentration of 100 mg/ml in 0.01 M sodium hydroxide and diluted appropriately with BGJb medium. In all experiments appropriate aliquots ofall vehicles were added to control incubations.
RESULTS
Basal resorption. DPH at a concentration of 100 jig/ml significantly inhibited basal 45Ca release from 5-day cultures of bone rudiments, whereas phenobarbital produced significant inhibition only at the highest concentration tested, 400 ,ug/ml (Fig. 1) . Control 45Ca release averaged 30.1 +±0.8% whereas freeze-thaw killed bone *Ca release averaged 14.2+0.4% (P < 0.001). The difference between these two values represents cell-mediated resorption. Because 45Ca release from killed bones was not significantly altered by DPH or phenobarbital in concentrations up to 400 ug/ml, the observed suppressive effects of these agents on 45Ca release must therefore reflect entirely an inhibition of cell-mediated processes.
When employed in combination at submaximal concentrations, DPH and phenobarbital had additive effects on active 45Ca release. The observed inhibition of resorption when DPH (50 ug/ml) was added in combination with phenobarbital (100 or 200 ,ug/ml) was virtually identical to what would have been predicted from inhibition produced by each drug individually (Table I) .
Hormonally stimulated resorption. The dose-response relationships of mediation of 45Ca release by synthetic PTH , synthetic human calcitonin (HCT), and 1,25-dihydroxyvitamin D3 [1,25-(OH)2D] were examined (Fig. 2 ). PTH produced a significant increase in 45Ca release at concentrations of2 ng/ml and above with maximal resorption achieved at 200 ng/ml. Significant stimulation by 1,25-(OH)2D was seen at a concentration of 0.1 ng/ml with maximal effect at 5 ng/ml. PTH-stimulated (50 ng/ml) resorption was significantly inhibited by HCT at 0.5 ng/ml and suppression to control values occurred at 20 ng/ml. No alteration of 45Ca release from freeze-killed bones was produced by any of these agents at the highest concentrations employed. In subsequent studies of the effects of DPH and phenobarbital on hormone-mediated resorption, hormone concentrations were em- ployed which were in the middle of their effective dose ranges. PTH-induced 45Ca release was significantly reduced by DPH at concentrations of25 ,ug/ml and above, whereas phenobarbital was effective in suppressing resorption only at concentrations of 100 gg/ml and higher (Fig. 3) .
Moreover, at comparable concentrations DPH produced significantly greater inhibition than did phenobarbital; e.g., 100j,g/ml (DPH, 33.9±3.2%; phenobarbital, 20.8±3.6%; P < 0.01), 200 ,ug/ml (DPH, 51.7±3.9; phenobarbital, 37.0±4.9% inhibition of PTH-stimulated value; P < 0.01). Additionally, PTH-stimulated resorption as measured by [3H]hydroxyproline release was significantly inhibited by both DPH and phenobarbital (Table II) , demonstrating that these agents inhibited matrix resorption as well as 45Ca release. On the other hand, 1,25-(OH)2D-stimulated resorption was somewhat less sensitive to drug inhibition, but significant suppression by DPH occurred at 100 ,ug/ml whereas phenobarbital was effective only at 200 ,ug/ml (Fig. 4) .
Again DPH produced significantly greater inhibition than did phenobarbital at both the 100-and 200-,ug/ml levels.
Because the drug concentrations employed in these studies were generally higher than those commonly obtained in vivo (17) ,ug/ml) for 24 h produced significant inhibition of PTHinduced (50 ng/ml) resorption, whereas lower concentrations of phenobarbital (100 and 200 ug/ml) did not produce a significant effect at this early time point (Table III) PTH-stimulated resorption. In parallel experiments, the comparative effects of DPH and phenobarbital in suppressing PTH-stimulated 45Ca release in the presence or absence ofHCT were examined (Table IV) . The data for each agent are expressed as both (a) the absolute percent resorption and (b) the resorption observed in the presence ofdrug at various concentrations This appeared to be the case for phenobarbital in concentrations ranging from 10 to 200 ,ug/ml. In contrast, DPH in concentrations of 25-200 ug/ml produced a significant, disproportionately greater percent inhibition of resorption in the presence of HCT. When the data were expressed as percent inhibition ofactive resorption (live bone minus killed bone resorption values) the synergism of effect was even more striking (Fig. 6 ). This synergism of action strongly suggests that DPH and HCT act at separate but interrelated sites in the cell-mediated resorption process. Additionally, the qualitative differences between the DPH and phenobarbital interactions with HCT suggest that these two drugs produce their effects on different and biochemical distinct aspects of the resorption process.
cAMP generation. After a 30-min incubation at 37°C in BGJb media containing 10 mM theophylline, control bone rudiment cAMP content averaged 0.71+0.08 pM/4 rudiments. After the addition of PTH (100 ng/ml) cAMP content rose rapidly, reaching a plateau at 4Y2 times basal levels by 7 min and remaining constant at this level through 20 or phenobarbital (400 ,ug/ml) for 24 h did not significantly alter basal cAMP content (Table V) . However, the increase in cAMP content produced by incubation with PTH at a concentration of 100 nglml was reduced by 38% by DPH (200 ,ug/ml) whereas phenobarbital (400 utglml) was without significant effect. HCT at a concentration of 5 ng/ml significantly increased both basal and PTH-stimulated cAMP content (Table V) , confirming previous reports of the additive effects of PTH and HCT in stimulating cAMP content in intact rat calvaria and in bone cells isolated from fetal rat calvaria (18, 19) . DPH at a concentration of 200 ,ug/ml reduced PTH plus HCT-stimulated cAMP content by 36%, a percentage reduction very similar to that produced by DPH in the presence of PTH alone (Table V) . This latter observation is in marked contrast to the striking synergistic effect of DPH with HCT in inhibiting 45Ca release at these same drug and hormone concentrations (Table IV, Figs. 5 and 6). These data would therefore suggest that DPH and HCT have additional direct inhibitory effects on bone resorption which are not mediated through inhibition of cAMP generation, and that it is at the cAMP unrelated site that DPH and HCT produce their synergistic effect. Phenobarbital produced a slight, but not statistically significant, reduction in PTH-HCT-stimulated cAMP formation, similar to its effects in the presence of PTH alone. 10-25 ,ug/ml (17) . However, DPH in serum is -90% protein bound (20) and as a result of the considerably lower concentration of protein present in the incubation medium relative to that in human serum, it is probable that the free DPH concentration in our cultures was higher than that occurring in vivo. On the other hand, because the drug effect was definitely dose-related over a 20-fold concentration range in vitro, it might be expected that lower concentrations acting over a longer time would produce effects in vivo similar to those observed in vitro. Although DPH and phenobarbital at submaximal concentrations were additive with regard to their inhibitory effects on resorption as assessed by 45Ca release, our data suggest that they may act at different sites in the resorption process. Whereas phenobarbital was merely additive to the inhibitory effect of HCT on PTH-induced resorption, DPH exhibited a synergistic interaction with HCT. This suggests that: (a) DPH and HCT act at separate but interrelated sites in the resorption process; and (b) the modes of action DPH and phenobarbital may be dissimilar.
Effects of Diphenylhydantoin and Phenobarbital on Bone Resorption
It is apparent that both DPH and phenobarbital inhibit bone resorption through cAMP-independent mechanisms because both agents inhibited 1,25-(OH)2D-induced resorption, a process previously shown to be independent of cAMP (21, 22) . However, in contrast to phenobarbital, DPH had additional effect on cAMP generation. DPH at a concentration of 200 ,ug/ml partially suppressed PTH-stimulated increases in rudiment cAMP content whereas phenobarbital at concentrations as high as 400 ,ug/ml had no statistically significant effects on cAMP generation. Because the stimulation of cAMP formation has been postulated to play an important role in PTH mediation of bone resorption (23) (24) (25) and because dibutyryl cAMP has been shown to mimic the resorptive effect of PTH on bone (25) , it is therefore possible that DPH may inhibit PTH-induced bone resorption through both cAMP-dependent and independent mechanisms.
The synergistic effect of DPH and HCT in suppressing PTH-stimulated 45Ca release is apparently not mediated through synergistic effects on cAMP generation. In initial experiments, we demonstrated that PTH and HCT both increased cAMP in intact long bone rudiments and that their effects on cAMP generation in this system were additive. These observations are in agreement with previous reports of the additive effects of PTH and calcitonin on cAMP generation in intact rat calvaria and in bone cells isolated from fetal rat calvaria (18, 19) . However, it was subsequently demonstrated that both PTH and PTH plus HCTstimulated cAMP generation were inhibited to a similar degree by DPH. Thus, the synergistic interaction of DPH and HCT apparently occurs through mechanisms independent of cAMP generation.
Jenkins and co-workers (26) have reported that DPH, but not phenobarbital, inhibits parathyroid extractstimulated 45Ca release from cultured mouse calvaria. However, they were unable to demonstrate any effect of DPH on cAMP generation. The basis for the divergence of these results from the findings of the present studies is unclear, but could be the result of species differences, recently demonstrated differences in the responsitivity of calvaria and long bones to certain resorptive stimuli (27) , or merely to differences in the concentrations of drug employed.
The precise mechanism by which DPH inhibits PTH-stimulated cAMP generation is at present undefined. It has been demonstrated that PTH stimulates calcium entry into bone cells, an effect which has been postulated to be important in the production of its biologic effects (28, 29) . This view is supported by the observation that calcium ionophore A23187, which has been shown to stimulate calcium uptake by bone cells in vitro (29) , can mimic certain of the effects of PTH on bone in vitro including stimulation of cAMP generation and enhancement of resorption (29, 30) . In this regard, it is of note that the anticonvulsant action of DPH has been shown to be mediated through suppression of post-tetanic potentiation, a process that is associated with the movement of calcium ions into the presynaptic area during stimulation (31) . This suppressive effect appears to be due primarily to an alteration in membrane transport of sodium ion with an indirect diminution of calcium influx (32) . Because there is evidence that transmembrane movement of sodium ion plays an important role in the cellular transport of calcium ion in both intestine and bone (33) (34) (35) , it could well be that DPH inhibition of membrane permeability to sodium reduces transmembrane calcium transport in these tissues as well. In support of this view, DPH has been shown to directly inhibit intestinal calcium transport in vivo under conditions in which vitamin D metabolism is apparently not altered (12) . Thus, the effect of DPH on PTH-induced cAMP generation could well occur via inhibitory effects on PTH-induced changes in intracellular calcium ion concentration. A similar inhibitory effect of DPH on calcium influx and stimulated cAMP generation has recently been demonstrated in mouse brain in vitro (36) . In addition, because calcitonin inhibits the efflux of calcium ion from bone cells (37) , the synergistic interaction of DPH and HCT could occur at the level of membrane transport of calcium ion. Moreover, it has been demonstrated that collagenase, an enzyme which apparently plays an important role in bone matrix dissolution, exhibits an absolute dependence for calcium ion (38) . Therefore, it is possible that DPH acts primarily by suppressing cell-mediated calcium release from bone, with a secondary reduction in collagenase activity and consequent inhibition of further matrix resorption.
Finally, the apparent divergent effects of DPH on bone metabolism raises the problem of reconciling the clinical observations that DPH can produce either calvarial thickening and tooth root abnormalities suggestive of diminished PTH effect (9) (10) (11) or histologic evidence of increased osteoclastic activity in association with a classic histologic pattern of osteomalacia (1 
